MINI-FUTURE SHORT - BB BIOTECH N Stock

Certificat

KBIO2U

CH1252969899

Real-time Bid/Ask 03:18:13 2024-05-29 EDT
0.38 CHF / 0.39 CHF +4.05% Intraday chart for MINI-FUTURE SHORT - BB BIOTECH N
Current month+5.71%
3 months+48.00%
Date Price Change
24-05-28 0.37 +2.78%
24-05-24 0.36 +2.86%

Delayed Quote Swiss Exchange

Last update May 28, 2024 at 11:20 am

More quotes

Static data

Product typeKnock-Out mit Stop Loss
Buy / SellPUT
Underlying BB BIOTECH AG
Issuer UBS
KBIO2U
ISINCH1252969899
Date issued 2023-02-24
Strike 51.43 CHF
Maturity Unlimited
Parity 30.03 : 1
Emission price 0.12 CHF
Emission volume N/A
Settlement Barausgleich
Currency CHF

Technical Indicators

Highest since issue 0.62 CHF
Lowest since issue 0.1 CHF
Spread 0.01 CHF
Spread %2.56%

Company Profile

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Sector
-
More about the company

Ratings for BB Biotech AG

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BB Biotech AG

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
40.15 CHF
Average target price
47.7 CHF
Spread / Average Target
+18.80%
Consensus
  1. Stock Market
  2. Certificates
  3. KBIO2U Certificat